The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats

Kidney International

Volumn 80, Issue 11, 2011, Pages 1182-1197

  Boor, Peter ^a,b   Celec, Peter ^c   Martin, Ina V ^b   Villa, Luigi ^b,d   Hodosy, Július ^c   Klenovicsová, Kristína ^a   Esposito, Ciro ^d   Schäfer, Stefan ^e   Albrecht Küpper, Barbara ^e   Ostendorf, Tammo ^b   Heidland, August ^f   Šebeková, Katarína ^c  

^a SLOVAK MEDICAL UNIVERSITY   (Slovakia)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Physics and Informatics   (Slovakia)

^d UNIVERSITY OF PAVIA   (Italy)

^e BAYER PHARMA AG   (Germany)

^f UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 [[4 [(2 METHOXYETHYL)6 [3 (TRIFLUOROMETHYL)PHENYL]PYRIMIDIN 4 YLAMINO]METHYLPHENYL]SULFANYL] 2 METHYLPROPANOIC ACID; FENOFIBRATE; FIBRONECTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PLACEBO; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENZYME REGULATION; FIBROBLAST; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY TUBULE CELL; MALE; NEPHRECTOMY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; TREATMENT RESPONSE;

EID: 81155131056     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2011.254     Document Type: Article

References (32)

1. Boor P, Sebekova K, Ostendorf T et al. Treatment targets in renal fibrosis. Nephrol Dial Transplant 2007; 22: 3391-3407. (Pubitemid 350212482)
2. Guan Y. Peroxisome proliferator-activated receptor family and its relationship to renal complications of the metabolic syndrome. J Am Soc Nephrol 2004; 15: 2801-2815. (Pubitemid 41103389)
3. Guan Y, Zhang Y, Davis L et al. Expression of peroxisome proliferatoractivated receptors in urinary tract of rabbits and humans. Am J Physiol 1997; 273: F1013-F1022.
4. Ruan XZ, Moorhead JF, Fernando R et al. PPAR agonists protect mesangial cells from interleukin 1beta-induced intracellular lipid accumulation by activating the ABCA1 cholesterol efflux pathway. J Am Soc Nephrol 2003; 14: 593-600. (Pubitemid 36246002)
5. Wilmer WA, Dixon CL, Hebert C et al. PPAR-alpha ligands inhibit H2O2-mediated activation of transforming growth factor-beta1 in human mesangial cells. Antioxid Redox Signal 2002; 4: 877-884. (Pubitemid 36042463)
6. Scholz-Pedretti K, Gans A, Beck KF et al. Potentiation of TNF-alphastimulated group IIA phospholipase A(2) expression by peroxisome proliferator-activated receptor alpha activators in rat mesangial cells. J Am Soc Nephrol 2002; 13: 611-620. (Pubitemid 34183925)
7. Li S, Basnakian A, Bhatt R et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990-F998. (Pubitemid 39391096)
8. Patel NS, di Paola R, Mazzon E et al. Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury. J Pharmacol Exp Ther 2009; 328: 635-643.
9. Park CW, Zhang Y, Zhang X et al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice. Kidney Int 2006; 69: 1511-1517.
10. Zhao X, Li LY. PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol 2008; 28: 598-606. (Pubitemid 351832447)
11. Kamijo Y, Hora K, Kono K et al. PPARalpha protects proximal tubular cells from acute fatty acid toxicity. J Am Soc Nephrol 2007; 18: 3089-3100. (Pubitemid 350223969)
12. Kamijo Y, Hora K, Nakajima T et al. Peroxisome proliferator-activated receptor alpha protects against glomerulonephritis induced by long-term exposure to the plasticizer di-(2-ethylhexyl)phthalate. J Am Soc Nephrol 2007; 18: 176-188. (Pubitemid 46053431)
13. Kamijo Y, Hora K, Tanaka N et al. Identification of functions of peroxisome proliferator-activated receptor alpha in proximal tubules. J Am Soc Nephrol 2002; 13: 1691-1702. (Pubitemid 34700593)
14. Ogata T, Miyauchi T, Irukayama-Tomobe Y et al. The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation. J Cardiovasc Pharmacol 2004; 44(Suppl 1): S279-S282. (Pubitemid 40039696)
15. Ogata T, Miyauchi T, Sakai S et al. Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway. J Am Coll Cardiol 2004; 43: 1481-1488. (Pubitemid 38496358)
16. Duhaney TA, Cui L, Rude MK et al. Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload. Hypertension 2007; 49: 1084-1094. (Pubitemid 351664324)
17. Toyama T, Nakamura H, Harano Y et al. PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem Biophys Res Commun 2004; 324: 697-704. (Pubitemid 39345573)
18. Linz W, Wohlfart P, Baader M et al. The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats. Acta Pharmacol Sin 2009; 30: 935-946.
19. Kawai T, Masaki T, Doi S et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab Invest 2009; 89: 47-58.
20. Chevalier RL. Obstructive nephropathy: towards biomarker discovery and gene therapy. Nat Clin Pract Nephrol 2006; 2: 157-168. (Pubitemid 43355195)
21. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002; 283: F861-F875. (Pubitemid 35192452)
22. Boor P, Konieczny A, Villa L et al. Complement c5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007; 18: 1508-1515. (Pubitemid 46717517)
23. Cho KH, Kim HJ, Kamanna VS et al. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim Biophys Acta 2009; 1800: 6-15.
24. Kim HJ, Moradi H, Yuan J et al. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am J Physiol Renal Physiol 2009; 296: F1297-F1306.
25. Braissant O, Foufelle F, Scotto C et al. Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-alpha,-beta, and-gamma in the adult rat. Endocrinology 1996; 137: 354-366. (Pubitemid 26005011)
26. Chinetti G, Griglio S, Antonucci M et al. Activation of proliferator-activated receptors alpha and gamma induces apoptosis of human monocytederived macrophages. J Biol Chem 1998; 273: 25573-25580. (Pubitemid 28475776)
27. Jones DC, Ding X, Daynes RA. Nuclear receptor peroxisome proliferatoractivated receptor alpha (PPARalpha) is expressed in resting murine lymphocytes. The PPARalpha in T and B lymphocytes is both transactivation and transrepression competent. J Biol Chem 2002; 277: 6838-6845. (Pubitemid 34953066)
28. Reynders V, Loitsch S, Steinhauer C et al. Peroxisome proliferatoractivated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes. Respir Res 2006; 7: 104.
29. Inoue I, Shino K, Noji S et al. Expression of peroxisome proliferatoractivated receptor alpha (PPAR alpha) in primary cultures of human vascular endothelial cells. Biochem Biophys Res Commun 1998; 246: 370-374. (Pubitemid 28412605)
30. Najib J. Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation. Clin Ther 2002; 24: 2022-2050. (Pubitemid 36051529)
31. Boor P, Konieczny A, Villa L et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol Dial Transplant 2007; 22: 1323-1331. (Pubitemid 47072219)
32. Boor P, Celec P, Behuliak M et al. Regular moderate exercise reduces advanced glycation and ameliorates early diabetic nephropathy in obese Zucker rats. Metabolism 2009; 58: 1669-1677.